In Section C, members will acquire ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment until eventually disease progression or the participants are unable to tolerate the study drugs. Over-all, our present work highlights the potential utilization of ARV-825 in combination with https://brd4-targeted-therapy-abb67801.pointblog.net/5-easy-facts-about-abbv-744-combination-therapy-with-chemotherapy-described-74596355